Sinai Medical Center Cedars

Sinai Medical Center Cedars is a declared insider at 2 companies; the most frequent names are Prometheus Biosciences, Inc. and Capricor Therapeutics, Inc. We count 9 filings; the first trade dates from 21 January 2015 and the latest from 16 March 2021.

Purchases make up the whole of the open-market record (4 purchases, €7.7M). Unlike grants, an open-market purchase is paid for by the insider, at the market price.

A typical purchase (the median) is worth €1.7M. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 50% of cases; the median change was -3.2%. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 16 March 2021: a transaction, in Prometheus Biosciences, Inc. The last insider purchase was made public on 11 May 2017, 3,469 days ago. Publication is fast: at least half of the trades appear on SEC (Form 4) on the same day. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.